Glaucoma surgery can reverse cupping

Article

Significantly more glaucoma patients, who are treated surgically rather than medically, will experience reversal of cupping.

Significantly more glaucoma patients, who are treated surgically rather than medically, will experience reversal of cupping, according to a study presented at the Pan-American Association of Ophthalmology congress in Cancun, Mexico.

Richard Parish, MD presented five-year data analysis from the Collaborative Initial Glaucoma Treatment Study (CIGTS). Investigators initially obtained optic disc photos from 607 patients with open angle glaucoma. Of these, 346 had follow-up photos of adequate quality, at the five-year mark, to be considered for analysis.

A total of 61 eyes were considered to have undergone changes of the optic disc and were sent to the CIGTS Optic Disc Endpoint Committee, which agreed on 45 of the 61 readings. They were surprised to discover that 25 of the eyes showed a reversal in optic disc cupping rather than the expected progression. The investigators found that 14% of patients treated surgically had undergone a reversal of cupping, compared with just 1% of those treated medically.

It was concluded that glaucoma surgery can, in some cases, reverse optic disc cupping.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.